Predictors of responses to immune checkpoint blockade in advanced melanoma.
Identifieur interne : 000489 ( PubMed/Corpus ); précédent : 000488; suivant : 000490Predictors of responses to immune checkpoint blockade in advanced melanoma.
Auteurs : N. Jacquelot ; M P Roberti ; D P Enot ; S. Rusakiewicz ; N. Ternès ; S. Jegou ; D M Woods ; A L Sodré ; M. Hansen ; Y. Meirow ; M. Sade-Feldman ; A. Burra ; S S Kwek ; C. Flament ; M. Messaoudene ; C P M. Duong ; L. Chen ; B S Kwon ; A C Anderson ; V K Kuchroo ; B. Weide ; F. Aubin ; C. Borg ; S. Dalle ; O. Beatrix ; M. Ayyoub ; B. Balme ; G. Tomasic ; A M Di Giacomo ; M. Maio ; D. Schadendorf ; I. Melero ; B. Dréno ; A. Khammari ; R. Dummer ; M. Levesque ; Y. Koguchi ; L. Fong ; M. Lotem ; M. Baniyash ; H. Schmidt ; I M Svane ; G. Kroemer ; A. Marabelle ; S. Michiels ; A. Cavalcanti ; M J Smyth ; J S Weber ; A M Eggermont ; L. ZitvogelSource :
- Nature communications [ 2041-1723 ] ; 2017.
Abstract
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8(+) T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.
DOI: 10.1038/s41467-017-00608-2
PubMed: 28928380
Links to Exploration step
pubmed:28928380Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of responses to immune checkpoint blockade in advanced melanoma.</title>
<author><name sortKey="Jacquelot, N" sort="Jacquelot, N" uniqKey="Jacquelot N" first="N" last="Jacquelot">N. Jacquelot</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Roberti, M P" sort="Roberti, M P" uniqKey="Roberti M" first="M P" last="Roberti">M P Roberti</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Enot, D P" sort="Enot, D P" uniqKey="Enot D" first="D P" last="Enot">D P Enot</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rusakiewicz, S" sort="Rusakiewicz, S" uniqKey="Rusakiewicz S" first="S" last="Rusakiewicz">S. Rusakiewicz</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ternes, N" sort="Ternes, N" uniqKey="Ternes N" first="N" last="Ternès">N. Ternès</name>
<affiliation><nlm:affiliation>University Paris-Saclay, Kremlin Bicêtre, 94 276, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jegou, S" sort="Jegou, S" uniqKey="Jegou S" first="S" last="Jegou">S. Jegou</name>
<affiliation><nlm:affiliation>Saint Antoine Hospital, INSERM ERL 1157-CNRS UMR 7203, Paris, 75005, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Woods, D M" sort="Woods, D M" uniqKey="Woods D" first="D M" last="Woods">D M Woods</name>
<affiliation><nlm:affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sodre, A L" sort="Sodre, A L" uniqKey="Sodre A" first="A L" last="Sodré">A L Sodré</name>
<affiliation><nlm:affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hansen, M" sort="Hansen, M" uniqKey="Hansen M" first="M" last="Hansen">M. Hansen</name>
<affiliation><nlm:affiliation>Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Meirow, Y" sort="Meirow, Y" uniqKey="Meirow Y" first="Y" last="Meirow">Y. Meirow</name>
<affiliation><nlm:affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sade Feldman, M" sort="Sade Feldman, M" uniqKey="Sade Feldman M" first="M" last="Sade-Feldman">M. Sade-Feldman</name>
<affiliation><nlm:affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burra, A" sort="Burra, A" uniqKey="Burra A" first="A" last="Burra">A. Burra</name>
<affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kwek, S S" sort="Kwek, S S" uniqKey="Kwek S" first="S S" last="Kwek">S S Kwek</name>
<affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Flament, C" sort="Flament, C" uniqKey="Flament C" first="C" last="Flament">C. Flament</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Messaoudene, M" sort="Messaoudene, M" uniqKey="Messaoudene M" first="M" last="Messaoudene">M. Messaoudene</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Duong, C P M" sort="Duong, C P M" uniqKey="Duong C" first="C P M" last="Duong">C P M. Duong</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, L" sort="Chen, L" uniqKey="Chen L" first="L" last="Chen">L. Chen</name>
<affiliation><nlm:affiliation>Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, New Haven, CT, 06519, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kwon, B S" sort="Kwon, B S" uniqKey="Kwon B" first="B S" last="Kwon">B S Kwon</name>
<affiliation><nlm:affiliation>Eutilex, Suite# 1401 Daeryung Technotown 17 Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, 08594, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Anderson, A C" sort="Anderson, A C" uniqKey="Anderson A" first="A C" last="Anderson">A C Anderson</name>
<affiliation><nlm:affiliation>Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kuchroo, V K" sort="Kuchroo, V K" uniqKey="Kuchroo V" first="V K" last="Kuchroo">V K Kuchroo</name>
<affiliation><nlm:affiliation>Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weide, B" sort="Weide, B" uniqKey="Weide B" first="B" last="Weide">B. Weide</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Medical Center Tübingen, Tübingen, 72076, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Aubin, F" sort="Aubin, F" uniqKey="Aubin F" first="F" last="Aubin">F. Aubin</name>
<affiliation><nlm:affiliation>Université de Franche Comté, EA3181, SFR4234, Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Besançon, 25000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Borg, C" sort="Borg, C" uniqKey="Borg C" first="C" last="Borg">C. Borg</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, University Hospital of Besancon, 3 Boulevard Alexander Fleming, Besancon, F-25030, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dalle, S" sort="Dalle, S" uniqKey="Dalle S" first="S" last="Dalle">S. Dalle</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Beatrix, O" sort="Beatrix, O" uniqKey="Beatrix O" first="O" last="Beatrix">O. Beatrix</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ayyoub, M" sort="Ayyoub, M" uniqKey="Ayyoub M" first="M" last="Ayyoub">M. Ayyoub</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Balme, B" sort="Balme, B" uniqKey="Balme B" first="B" last="Balme">B. Balme</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tomasic, G" sort="Tomasic, G" uniqKey="Tomasic G" first="G" last="Tomasic">G. Tomasic</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Di Giacomo, A M" sort="Di Giacomo, A M" uniqKey="Di Giacomo A" first="A M" last="Di Giacomo">A M Di Giacomo</name>
<affiliation><nlm:affiliation>Medical Oncology and Immunotherapy Division, University Hospital of Siena, Viale Bracci, 14, Siena, 53100, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Maio, M" sort="Maio, M" uniqKey="Maio M" first="M" last="Maio">M. Maio</name>
<affiliation><nlm:affiliation>Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Instituto Toscano Tumori, Siena, 53100, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D" last="Schadendorf">D. Schadendorf</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany & German Cancer Consortium (DKTZ), Heidelberg, D-69120, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Melero, I" sort="Melero, I" uniqKey="Melero I" first="I" last="Melero">I. Melero</name>
<affiliation><nlm:affiliation>Division of Gene Therapy and Hepatology, Centre for Applied Medical Research, Pamplona, 31008, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B" last="Dréno">B. Dréno</name>
<affiliation><nlm:affiliation>Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Khammari, A" sort="Khammari, A" uniqKey="Khammari A" first="A" last="Khammari">A. Khammari</name>
<affiliation><nlm:affiliation>Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R" last="Dummer">R. Dummer</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Levesque, M" sort="Levesque, M" uniqKey="Levesque M" first="M" last="Levesque">M. Levesque</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Koguchi, Y" sort="Koguchi, Y" uniqKey="Koguchi Y" first="Y" last="Koguchi">Y. Koguchi</name>
<affiliation><nlm:affiliation>Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fong, L" sort="Fong, L" uniqKey="Fong L" first="L" last="Fong">L. Fong</name>
<affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lotem, M" sort="Lotem, M" uniqKey="Lotem M" first="M" last="Lotem">M. Lotem</name>
<affiliation><nlm:affiliation>Sharett Institute of Oncology, Hadassah Medical Organization, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Baniyash, M" sort="Baniyash, M" uniqKey="Baniyash M" first="M" last="Baniyash">M. Baniyash</name>
<affiliation><nlm:affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schmidt, H" sort="Schmidt, H" uniqKey="Schmidt H" first="H" last="Schmidt">H. Schmidt</name>
<affiliation><nlm:affiliation>Department of Oncology, Aarhus University Hospital, Aarhus, DK-8200, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Svane, I M" sort="Svane, I M" uniqKey="Svane I" first="I M" last="Svane">I M Svane</name>
<affiliation><nlm:affiliation>Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kroemer, G" sort="Kroemer, G" uniqKey="Kroemer G" first="G" last="Kroemer">G. Kroemer</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Marabelle, A" sort="Marabelle, A" uniqKey="Marabelle A" first="A" last="Marabelle">A. Marabelle</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Michiels, S" sort="Michiels, S" uniqKey="Michiels S" first="S" last="Michiels">S. Michiels</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cavalcanti, A" sort="Cavalcanti, A" uniqKey="Cavalcanti A" first="A" last="Cavalcanti">A. Cavalcanti</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name>
<affiliation><nlm:affiliation>Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weber, J S" sort="Weber, J S" uniqKey="Weber J" first="J S" last="Weber">J S Weber</name>
<affiliation><nlm:affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Eggermont, A M" sort="Eggermont, A M" uniqKey="Eggermont A" first="A M" last="Eggermont">A M Eggermont</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zitvogel, L" sort="Zitvogel, L" uniqKey="Zitvogel L" first="L" last="Zitvogel">L. Zitvogel</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France. Laurence.ZITVOGEL@gustaveroussy.fr.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28928380</idno>
<idno type="pmid">28928380</idno>
<idno type="doi">10.1038/s41467-017-00608-2</idno>
<idno type="wicri:Area/PubMed/Corpus">000489</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000489</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of responses to immune checkpoint blockade in advanced melanoma.</title>
<author><name sortKey="Jacquelot, N" sort="Jacquelot, N" uniqKey="Jacquelot N" first="N" last="Jacquelot">N. Jacquelot</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Roberti, M P" sort="Roberti, M P" uniqKey="Roberti M" first="M P" last="Roberti">M P Roberti</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Enot, D P" sort="Enot, D P" uniqKey="Enot D" first="D P" last="Enot">D P Enot</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rusakiewicz, S" sort="Rusakiewicz, S" uniqKey="Rusakiewicz S" first="S" last="Rusakiewicz">S. Rusakiewicz</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ternes, N" sort="Ternes, N" uniqKey="Ternes N" first="N" last="Ternès">N. Ternès</name>
<affiliation><nlm:affiliation>University Paris-Saclay, Kremlin Bicêtre, 94 276, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jegou, S" sort="Jegou, S" uniqKey="Jegou S" first="S" last="Jegou">S. Jegou</name>
<affiliation><nlm:affiliation>Saint Antoine Hospital, INSERM ERL 1157-CNRS UMR 7203, Paris, 75005, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Woods, D M" sort="Woods, D M" uniqKey="Woods D" first="D M" last="Woods">D M Woods</name>
<affiliation><nlm:affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sodre, A L" sort="Sodre, A L" uniqKey="Sodre A" first="A L" last="Sodré">A L Sodré</name>
<affiliation><nlm:affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hansen, M" sort="Hansen, M" uniqKey="Hansen M" first="M" last="Hansen">M. Hansen</name>
<affiliation><nlm:affiliation>Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Meirow, Y" sort="Meirow, Y" uniqKey="Meirow Y" first="Y" last="Meirow">Y. Meirow</name>
<affiliation><nlm:affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sade Feldman, M" sort="Sade Feldman, M" uniqKey="Sade Feldman M" first="M" last="Sade-Feldman">M. Sade-Feldman</name>
<affiliation><nlm:affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burra, A" sort="Burra, A" uniqKey="Burra A" first="A" last="Burra">A. Burra</name>
<affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kwek, S S" sort="Kwek, S S" uniqKey="Kwek S" first="S S" last="Kwek">S S Kwek</name>
<affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Flament, C" sort="Flament, C" uniqKey="Flament C" first="C" last="Flament">C. Flament</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Messaoudene, M" sort="Messaoudene, M" uniqKey="Messaoudene M" first="M" last="Messaoudene">M. Messaoudene</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Duong, C P M" sort="Duong, C P M" uniqKey="Duong C" first="C P M" last="Duong">C P M. Duong</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, L" sort="Chen, L" uniqKey="Chen L" first="L" last="Chen">L. Chen</name>
<affiliation><nlm:affiliation>Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, New Haven, CT, 06519, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kwon, B S" sort="Kwon, B S" uniqKey="Kwon B" first="B S" last="Kwon">B S Kwon</name>
<affiliation><nlm:affiliation>Eutilex, Suite# 1401 Daeryung Technotown 17 Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, 08594, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Anderson, A C" sort="Anderson, A C" uniqKey="Anderson A" first="A C" last="Anderson">A C Anderson</name>
<affiliation><nlm:affiliation>Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kuchroo, V K" sort="Kuchroo, V K" uniqKey="Kuchroo V" first="V K" last="Kuchroo">V K Kuchroo</name>
<affiliation><nlm:affiliation>Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weide, B" sort="Weide, B" uniqKey="Weide B" first="B" last="Weide">B. Weide</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Medical Center Tübingen, Tübingen, 72076, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Aubin, F" sort="Aubin, F" uniqKey="Aubin F" first="F" last="Aubin">F. Aubin</name>
<affiliation><nlm:affiliation>Université de Franche Comté, EA3181, SFR4234, Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Besançon, 25000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Borg, C" sort="Borg, C" uniqKey="Borg C" first="C" last="Borg">C. Borg</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, University Hospital of Besancon, 3 Boulevard Alexander Fleming, Besancon, F-25030, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dalle, S" sort="Dalle, S" uniqKey="Dalle S" first="S" last="Dalle">S. Dalle</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Beatrix, O" sort="Beatrix, O" uniqKey="Beatrix O" first="O" last="Beatrix">O. Beatrix</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ayyoub, M" sort="Ayyoub, M" uniqKey="Ayyoub M" first="M" last="Ayyoub">M. Ayyoub</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Balme, B" sort="Balme, B" uniqKey="Balme B" first="B" last="Balme">B. Balme</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tomasic, G" sort="Tomasic, G" uniqKey="Tomasic G" first="G" last="Tomasic">G. Tomasic</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Di Giacomo, A M" sort="Di Giacomo, A M" uniqKey="Di Giacomo A" first="A M" last="Di Giacomo">A M Di Giacomo</name>
<affiliation><nlm:affiliation>Medical Oncology and Immunotherapy Division, University Hospital of Siena, Viale Bracci, 14, Siena, 53100, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Maio, M" sort="Maio, M" uniqKey="Maio M" first="M" last="Maio">M. Maio</name>
<affiliation><nlm:affiliation>Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Instituto Toscano Tumori, Siena, 53100, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D" last="Schadendorf">D. Schadendorf</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany & German Cancer Consortium (DKTZ), Heidelberg, D-69120, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Melero, I" sort="Melero, I" uniqKey="Melero I" first="I" last="Melero">I. Melero</name>
<affiliation><nlm:affiliation>Division of Gene Therapy and Hepatology, Centre for Applied Medical Research, Pamplona, 31008, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B" last="Dréno">B. Dréno</name>
<affiliation><nlm:affiliation>Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Khammari, A" sort="Khammari, A" uniqKey="Khammari A" first="A" last="Khammari">A. Khammari</name>
<affiliation><nlm:affiliation>Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R" last="Dummer">R. Dummer</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Levesque, M" sort="Levesque, M" uniqKey="Levesque M" first="M" last="Levesque">M. Levesque</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Koguchi, Y" sort="Koguchi, Y" uniqKey="Koguchi Y" first="Y" last="Koguchi">Y. Koguchi</name>
<affiliation><nlm:affiliation>Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fong, L" sort="Fong, L" uniqKey="Fong L" first="L" last="Fong">L. Fong</name>
<affiliation><nlm:affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lotem, M" sort="Lotem, M" uniqKey="Lotem M" first="M" last="Lotem">M. Lotem</name>
<affiliation><nlm:affiliation>Sharett Institute of Oncology, Hadassah Medical Organization, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Baniyash, M" sort="Baniyash, M" uniqKey="Baniyash M" first="M" last="Baniyash">M. Baniyash</name>
<affiliation><nlm:affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schmidt, H" sort="Schmidt, H" uniqKey="Schmidt H" first="H" last="Schmidt">H. Schmidt</name>
<affiliation><nlm:affiliation>Department of Oncology, Aarhus University Hospital, Aarhus, DK-8200, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Svane, I M" sort="Svane, I M" uniqKey="Svane I" first="I M" last="Svane">I M Svane</name>
<affiliation><nlm:affiliation>Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kroemer, G" sort="Kroemer, G" uniqKey="Kroemer G" first="G" last="Kroemer">G. Kroemer</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Marabelle, A" sort="Marabelle, A" uniqKey="Marabelle A" first="A" last="Marabelle">A. Marabelle</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Michiels, S" sort="Michiels, S" uniqKey="Michiels S" first="S" last="Michiels">S. Michiels</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cavalcanti, A" sort="Cavalcanti, A" uniqKey="Cavalcanti A" first="A" last="Cavalcanti">A. Cavalcanti</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name>
<affiliation><nlm:affiliation>Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weber, J S" sort="Weber, J S" uniqKey="Weber J" first="J S" last="Weber">J S Weber</name>
<affiliation><nlm:affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Eggermont, A M" sort="Eggermont, A M" uniqKey="Eggermont A" first="A M" last="Eggermont">A M Eggermont</name>
<affiliation><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zitvogel, L" sort="Zitvogel, L" uniqKey="Zitvogel L" first="L" last="Zitvogel">L. Zitvogel</name>
<affiliation><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France. Laurence.ZITVOGEL@gustaveroussy.fr.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature communications</title>
<idno type="eISSN">2041-1723</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8(+) T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">28928380</PMID>
<DateCreated><Year>2017</Year>
<Month>09</Month>
<Day>20</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>8</Volume>
<Issue>1</Issue>
<PubDate><Year>2017</Year>
<Month>Sep</Month>
<Day>19</Day>
</PubDate>
</JournalIssue>
<Title>Nature communications</Title>
<ISOAbbreviation>Nat Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Predictors of responses to immune checkpoint blockade in advanced melanoma.</ArticleTitle>
<Pagination><MedlinePgn>592</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-017-00608-2</ELocationID>
<Abstract><AbstractText>Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8(+) T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacquelot</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University Paris-Saclay, Kremlin Bicêtre, 94 276, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roberti</LastName>
<ForeName>M P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Enot</LastName>
<ForeName>D P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rusakiewicz</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ternès</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>University Paris-Saclay, Kremlin Bicêtre, 94 276, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy, Université Paris-Saclay, Service de Biostatistique et d'Epidémiologie, Villejuif, F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jegou</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Saint Antoine Hospital, INSERM ERL 1157-CNRS UMR 7203, Paris, 75005, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Woods</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sodré</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo><Affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hansen</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Meirow</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sade-Feldman</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burra</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kwek</LastName>
<ForeName>S S</ForeName>
<Initials>SS</Initials>
<AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Flament</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University Paris-Saclay, Kremlin Bicêtre, 94 276, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Messaoudene</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Duong</LastName>
<ForeName>C P M</ForeName>
<Initials>CPM</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, New Haven, CT, 06519, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kwon</LastName>
<ForeName>B S</ForeName>
<Initials>BS</Initials>
<AffiliationInfo><Affiliation>Eutilex, Suite# 1401 Daeryung Technotown 17 Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, 08594, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, 70112, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anderson</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo><Affiliation>Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kuchroo</LastName>
<ForeName>V K</ForeName>
<Initials>VK</Initials>
<AffiliationInfo><Affiliation>Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weide</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Medical Center Tübingen, Tübingen, 72076, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Aubin</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Université de Franche Comté, EA3181, SFR4234, Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Besançon, 25000, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Borg</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, University Hospital of Besancon, 3 Boulevard Alexander Fleming, Besancon, F-25030, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Clinical Investigational Centre, CIC-1431, University Hospital of Besançon, Besançon, 25030, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>INSERM U1098, University of Franche-Comté, Besançon, 25020, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dalle</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Centre de Recherche en Cancérologie de Lyon, Lyon, 69000, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Beatrix</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ayyoub</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Balme</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, 69000, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tomasic</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Di Giacomo</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Medical Oncology and Immunotherapy Division, University Hospital of Siena, Viale Bracci, 14, Siena, 53100, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maio</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Instituto Toscano Tumori, Siena, 53100, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schadendorf</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany & German Cancer Consortium (DKTZ), Heidelberg, D-69120, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Melero</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Division of Gene Therapy and Hepatology, Centre for Applied Medical Research, Pamplona, 31008, Spain.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Oncology Department, University Clinic of Navarra, Pamplona, 31008, Spain.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Centro de Investigación cBiomedica en Red de Oncologia, Pamplona, 31008, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dréno</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khammari</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dummer</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levesque</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Koguchi</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fong</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lotem</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Sharett Institute of Oncology, Hadassah Medical Organization, Jerusalem, 91120, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baniyash</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schmidt</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Oncology, Aarhus University Hospital, Aarhus, DK-8200, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Svane</LastName>
<ForeName>I M</ForeName>
<Initials>IM</Initials>
<AffiliationInfo><Affiliation>Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kroemer</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>INSERM U1138, Centre de Recherche des Cordeliers, Paris, 75006, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, 75006, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Université Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Université Pierre et Marie Curie, Paris, 75005, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, 75015, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marabelle</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Michiels</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy, Université Paris-Saclay, Service de Biostatistique et d'Epidémiologie, Villejuif, F-94805, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cavalcanti</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Surgery, Gustave Roussy Cancer Center, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Dermatology, Gustave Roussy Cancer Center, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smyth</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-7098-7240</Identifier>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>School of Medicine, University of Queensland, Herston, QLD, 4006, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weber</LastName>
<ForeName>J S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo><Affiliation>Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eggermont</LastName>
<ForeName>A M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zitvogel</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France. Laurence.ZITVOGEL@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University Paris-Saclay, Kremlin Bicêtre, 94 276, France. Laurence.ZITVOGEL@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, 94800, France. Laurence.ZITVOGEL@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France. Laurence.ZITVOGEL@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy, Université Paris-Saclay, Service de Biostatistique et d'Epidémiologie, Villejuif, F-94805, France. Laurence.ZITVOGEL@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>09</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nat Commun</MedlineTA>
<NlmUniqueID>101528555</NlmUniqueID>
<ISSNLinking>2041-1723</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2016 Jan;126(1):318-34</RefSource>
<PMID Version="1">26657860</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2015 Apr 13;27(4):450-61</RefSource>
<PMID Version="1">25858804</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2005 Nov 20;117(4):596-604</RefSource>
<PMID Version="1">15945101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immun. 2010 Oct 20;10 :9</RefSource>
<PMID Version="1">20957980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Res. 2016 Apr;4(4):345-53</RefSource>
<PMID Version="1">26873574</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pathol Oncol Res. 2009 Jun;15(2):241-50</RefSource>
<PMID Version="1">19015953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jul 1;28(19):3167-75</RefSource>
<PMID Version="1">20516446</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Res. 2013 Oct;1(4):229-34</RefSource>
<PMID Version="1">24777852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2015 Dec 1;75(23 ):5084-92</RefSource>
<PMID Version="1">26627641</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Nov 27;515(7528):568-71</RefSource>
<PMID Version="1">25428505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Res. 2014 Aug;2(8):812-21</RefSource>
<PMID Version="1">24844912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Res. 2015 Feb;25(2):208-24</RefSource>
<PMID Version="1">25582080</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2015 Jun;42(3):448-58</RefSource>
<PMID Version="1">25965363</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncoimmunology. 2016 Sep 20;5(11):e1235107</RefSource>
<PMID Version="1">27999753</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Jun 15;22(12):2908-18</RefSource>
<PMID Version="1">26787752</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2016 May;136(5):994-1001</RefSource>
<PMID Version="1">26829031</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 1999 Nov;5(11):3529-33</RefSource>
<PMID Version="1">10589768</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Respir Med. 2013 Sep;1(7):551-63</RefSource>
<PMID Version="1">24461616</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Leukoc Biol. 2015 Nov;98(5):739-59</RefSource>
<PMID Version="1">26246489</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2009 Dec 1;15(23 ):7412-20</RefSource>
<PMID Version="1">19934295</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 May 21;372(21):2006-17</RefSource>
<PMID Version="1">25891304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Dec 19;8(12):e84927</RefSource>
<PMID Version="1">24367702</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2015 Sep 15;21(18):4035-9</RefSource>
<PMID Version="1">26374073</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2015 Mar 25;7(280):280ps7</RefSource>
<PMID Version="1">25810311</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Oncol. 2015 Dec;9(10 ):2043-53</RefSource>
<PMID Version="1">26548534</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Dermatol. 2002 Jul;147(1):80-6</RefSource>
<PMID Version="1">12100188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Oct 1;19(19):5542</RefSource>
<PMID Version="1">24048329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Dec 4;371(23 ):2189-2199</RefSource>
<PMID Version="1">25409260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Immunother. 2012 Jul;61(7):1019-31</RefSource>
<PMID Version="1">22146893</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell. 2015 Apr 9;161(2):185-6</RefSource>
<PMID Version="1">26042237</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2016 Nov;17 (11):1558-1568</RefSource>
<PMID Version="1">27622997</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2015 Aug 1;21(15):3428-35</RefSource>
<PMID Version="1">25869385</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2013 Jul 11;499(7457):214-218</RefSource>
<PMID Version="1">23770567</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2015 Aug;12(8):438</RefSource>
<PMID Version="1">26077044</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2016 Mar 1;126(3):921-37</RefSource>
<PMID Version="1">26854930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2006;45(2):175-83</RefSource>
<PMID Version="1">16546863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97</RefSource>
<PMID Version="1">20826737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Autophagy. 2015;11(10):1878-90</RefSource>
<PMID Version="1">26506894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Transl Med. 2011 Nov 28;9:204</RefSource>
<PMID Version="1">22123319</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2013 Nov 15;73(22):6711-21</RefSource>
<PMID Version="1">24072745</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2012 Mar 28;4(127):127ps8</RefSource>
<PMID Version="1">22461638</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Dec 1;22(23 ):5661-5672</RefSource>
<PMID Version="1">27178742</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell. 2015 Sep 10;162(6):1242-56</RefSource>
<PMID Version="1">26359984</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2010 Oct;37(5):508-16</RefSource>
<PMID Version="1">21074066</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2015 Nov 15;21(22):4989-91</RefSource>
<PMID Version="1">26567357</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Mar 1;383(9919):816-27</RefSource>
<PMID Version="1">24054424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Histopathology. 2015 Jan;66(2):289-99</RefSource>
<PMID Version="1">25314639</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 May;16(5):522-30</RefSource>
<PMID Version="1">25840693</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2014 Jun;20(6):607-15</RefSource>
<PMID Version="1">24793239</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Nov 15;22(22):5487-5496</RefSource>
<PMID Version="1">27185375</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 May 21;372(21):2018-28</RefSource>
<PMID Version="1">25891174</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Nov 10;375(19):1845-1855</RefSource>
<PMID Version="1">27717298</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Apr 1;116(7):1767-75</RefSource>
<PMID Version="1">20143434</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2017 Jan;18(1):31-41</RefSource>
<PMID Version="1">27932067</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jul 2;373(1):23-34</RefSource>
<PMID Version="1">26027431</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2012 Mar 28;4(127):127ra37</RefSource>
<PMID Version="1">22461641</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Jun;24(6):1697-703</RefSource>
<PMID Version="1">23439861</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncoimmunology. 2016 Apr 25;6(1):e1137418</RefSource>
<PMID Version="1">28197361</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jul 29;363(5):411-22</RefSource>
<PMID Version="1">20818862</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Surg. 2003 Jan;27(1):10-3</RefSource>
<PMID Version="1">12557031</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Transl Med. 2005 Mar 02;3(1):10</RefSource>
<PMID Version="1">15740633</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell. 2016 Dec 1;167(6):1540-1554.e12</RefSource>
<PMID Version="1">27912061</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Rep. 2015 Oct 13;13(2):412-24</RefSource>
<PMID Version="1">26411680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2001 May;7(5):1282-6</RefSource>
<PMID Version="1">11350895</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Mar 20;33(9):983-91</RefSource>
<PMID Version="1">25534375</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Aug;24(8):2174-80</RefSource>
<PMID Version="1">23666915</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pathol Oncol Res. 2012 Oct;18(4):841-8</RefSource>
<PMID Version="1">22422199</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jun 28;366(26):2455-65</RefSource>
<PMID Version="1">22658128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 2016 Nov;48(11):1327-1329</RefSource>
<PMID Version="1">27668655</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>02</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>07</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28928380</ArticleId>
<ArticleId IdType="doi">10.1038/s41467-017-00608-2</ArticleId>
<ArticleId IdType="pii">10.1038/s41467-017-00608-2</ArticleId>
<ArticleId IdType="pmc">PMC5605517</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000489 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000489 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:28928380 |texte= Predictors of responses to immune checkpoint blockade in advanced melanoma. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28928380" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |